Piper Jaffray Initiates Coverage on Vertex Pharmaceuticals (VRTX) with a Buy
More News related to VRTX
- Vertex Pharmaceuticals Announces Agreements to Exchange $109.0 Million of its 2013 Convertible Senior Subordinated Notes into Common Stock
- Vertex Pharma (VRTX) January puts spreaders active on low volatility
- Morgan Stanley Upgrades Vertex (VRTX) to Overweight
- Analysts Mixed as Results from Trial of Vertex's Telaprevir Send the Stock Higher (VRTX)
- Unusual 11 Mid-Day Movers 11/02: HGSI, EAC, IUSA, VRTX Higher; CIT, YRCW, GTXI, CPF Lower
More News related to New Coverage
- Morgan Stanley Starts ONEOK (OKE) at Underweight, $40 Price Target
- Broadpoint.Amtech Initiates Coverage on Willbros Group (WG) with a Buy; Leading North American Pipeline Contractor
- Miller Tabak Initiates Coverage on Oclaro (OCLR) with a Buy
- Natixis Bleichroeder Initiates Coverage on Gen-Probe (GPRO) with a Buy
- Craig-Hallum Initiates Coverage on Onyx Pharmaceuticals (ONXX) with a Buy
Piper Jaffray & Co. initiates coverage on Vertex Pharmaceuticals (Nasdaq: VRTX) with a Buy. Price target $43.
Piper analyst says, "Vertex is one of the few biotech companies today that we believe can deliver a true blockbuster drug in the next few years. As a result, we expect VRTX shares to appreciate significantly over the next 12-months ahead of Phase III data and approval. Huge market opportunity makes Vertex an attractive acquisition candidate for Big Pharma, in our view."
Vertex Pharmaceuticals Incorporated (Vertex) is a biotechnology company in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases.
Related Categories
New CoverageStocks Mentioned
+0.27Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
